{"organizations": [], "uuid": "749b05767f868db78c7c158edb8138c038a14ac6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ose-immunotherapeutics-to-resume-p/brief-ose-immunotherapeutics-to-resume-patient-accrual-in-u-s-for-phase-3-tedopi-clinical-trial-idUSASB0C7LL", "country": "US", "domain_rank": 408, "title": "BRIEF-Ose Immunotherapeutics To Resume Patient Accrual In U. S. For Phase 3 Tedopi Clinical Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T08:43:00.000+02:00", "replies_count": 0, "uuid": "749b05767f868db78c7c158edb8138c038a14ac6"}, "author": "", "url": "https://www.reuters.com/article/brief-ose-immunotherapeutics-to-resume-p/brief-ose-immunotherapeutics-to-resume-patient-accrual-in-u-s-for-phase-3-tedopi-clinical-trial-idUSASB0C7LL", "ord_in_thread": 0, "title": "BRIEF-Ose Immunotherapeutics To Resume Patient Accrual In U. S. For Phase 3 Tedopi Clinical Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "tedopi clinical trial reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 27, 2018 / 6:43 AM / Updated 2 minutes ago BRIEF-Ose Immunotherapeutics To Resume Patient Accrual In U. S. For Phase 3 Tedopi Clinical Trial Reuters Staff 1 Min Read Feb 27 (Reuters) - OSE IMMUNOTHERAPEUTICS SA: * OSE IMMUNOTHERAPEUTICS GRANTED APPROVAL TO RESUME PATIENT ACCRUAL IN U. S. FOR PHASE 3 TEDOPI CLINICAL TRIAL IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS FOLLOWING IMMUNE CHECKPOINT INHIBITOR TREATMENT * TRIAL WILL BE CONDUCTED IN TWO STEPS * PHASE 1: ENROLLMENT OF AROUND 100 PATIENTS AND PERFORMANCE ANALYSIS OF SURVIVAL DATA * PHASE 1: RESULTS EXPECTED IN APPROXIMATELY TWO YEARS * BASED ON PHASE 1 RESULTS WILL DETERMINE PHASE 2 * PRIMARY ENDPOINT OF TRIAL IS OVERALL SURVIVAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)", "external_links": [], "published": "2018-02-27T08:43:00.000+02:00", "crawled": "2018-02-27T08:47:11.009+02:00", "highlightTitle": ""}